Application Nr Approved Date Route Status External Links
NDA212526 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Piqray Is Indicated In Combination With Fulvestrant For The Treatment Of Postmenopausal Women, And Men, With Hormone Receptor (Hr)-Positive, Human Epidermal Growth Factor Receptor 2 (Her2)-Negative, Pik3ca-Mutated, Advanced Or Metastatic Breast Cancer As Detected By An Fda-Approved Test Following Progression On Or After An Endocrine-Based Regimen. Piqray Is A Kinase Inhibitor Indicated In Combination With Fulvestrant For The Treatment Of Postmenopausal Women, And Men, With Hormone Receptor (Hr)-Positive, Human Epidermal Growth Factor Receptor 2 (Her2)-Negative, Pik3ca-Mutated, Advanced Or Metastatic Breast Cancer As Detected By An Fda-Approved Test Following Progression On Or After An Endocrine-Based Regimen.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Alpelisib

Comments